Press Сentre
Company news
Chromis, a joint venture of the Russian Direct Investment Fund (RDIF) and ChemRar Group, was rated by Rospatent among Russia’s TOP 100 Inventions for the second half of 2020 and was awarded a diploma for the development of a favipiravir-based formulation Avifavir® — the world's first medicine registered for COVID-19 treatment. In addition to ...
17.06.2021
The high efficacy of Avifavir®, the first registered drug for the treatment of COVID-19, in clinical practice was recognized at the All-Russian Congress on Infectious Diseases.
Last week saw the closing of the 13th All-Russian Congress on Infectious Diseases named after academician V.I. Pokrovsky “Infectious Diseases in the Modern World: Current ...
08.06.2021
Indonesia registers Russian drug with proven clinical efficacy against coronavirus
Avifavir was the first Favipiravir-based drug in the world approved for the treatment of coronavirus and the first drug registered in Russia to treat coronavirus
Moscow, March 24, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) ...
24.03.2021
Chromis (Russia), a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF), and its partner Viriom Inc., a San Diego CA-based biotech reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic ...
10.03.2021
The results of the two phases of the clinical trial of Avifavir for coronavirus treatment were presented at the “COVID-19: Pandemic of the XXI Century” International Congress held in Ufa on November 13–14. More than 3,500 experts from 8 countries (Russia, China, USA, Germany, Uzbekistan, Kazakhstan, Tajikistan, and Ukraine) took part in the ...
20.11.2020
Under the Government order on financing the purchase of drugs for the treatment of outpatients with the COVID-19 infection, the drug will be free of charge;
The joint venture formed by RDIF and ChemRar Group will double the drug’s production volume to 200,000 packs of Avifavir per month;
The permanent registration certificate for the drug as a ...
09.11.2020
Efficacy of favipiravir-based drugs against COVID-19 has been confirmed by clinical trials in Russia and Japan
Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan have already received Avifavir, deliveries to 17 more countries are expected
Moscow, September 24, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s ...
24.09.2020
Moscow, September 23, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce measures to increase the availability of Avifavir, the world's first favipiravir-based drug registered against coronavirus infection and Russia’s first drug approved for the treatment of COVID-19.
Efficacy of ...
23.09.2020
Moscow, September 21, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce the start of deliveries of Avifavir, the first Russian drug approved to treat coronavirus infection, to Bolivia and other countries in Latin America. The partners have announced earlier the agreement to deliver ...
21.09.2020
Moscow, August 3, 2020 – Chromis, a joint venture established by the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce the signing of an exclusive agreement with Bolivia’s Sigma Corp S.R.L. (Industria Quimico Farmaceutica Sigma Corp S.R.L.) to deliver the first Russian anti-COVID drug Avifavir to ...
03.08.2020
Moscow, August 3, 2020 – Chromis, a joint venture established by the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group, announce the signing of a distribution agreement with South Africa’s 3Sixty Biopharmaceuticals, a subsidiary of 3Sixty Global Solutions Group, to deliver Avifavir, the first Russian ...
03.08.2020
Research and Development institute “ChemRar” has created a unique platform for innovation drug discovery against novel coronavirus infection. The platform includes library of pharmaceutical relevant antiviral (SARS-CoV-2) small molecules, methods of virtual screening and in-vitro assays allowing to identify the active compounds in high-throughput ...
20.07.2020
Videos
Photos
Copyright © 2021 HTC "Chemrar"